Neurokinin-1 receptor: a new promising target in the treatment of cancer.
Muñoz
Miguel
M
Research Laboratory on Neuropeptides, Hospital Infantil Universitario Virgen del Rocío, Sevilla 41013, Spain. mmunoz@cica.es
Coveñas
Rafael
R
D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D017209:Apoptosis / Q000187:drug effects; D049109:Cell Proliferation / Q000187:drug effects; D006801:Humans; D058990:Molecular Targeted Therapy / Q000379:methods* / Q000639:trends; D009369:Neoplasms / Q000098:blood supply / Q000188:drug therapy* / Q000473:pathology; D064729:Neurokinin-1 Receptor Antagonists; D018040:Receptors, Neurokinin-1 / Q000235:genetics / Q000378:metabolism / Q000502:physiology*; D013373:Substance P / Q000235:genetics / Q000378:metabolism / Q000502:physiology
D000970:Antineoplastic Agents; D064729:Neurokinin-1 Receptor Antagonists; D018040:Receptors, Neurokinin-1; D013373:Substance P